Acamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
- 1 March 2010
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 9 (1) , 23-32
Abstract
Alcoholism is one of the most prevalent substance dependence disorders in the world. Advances in research in the neurobiological mechanisms underlying alcohol dependence have identified specific neurotransmitter targets for the development of pharmacological treatments. Acamprosate, marketed under the brand name Campral, is an orally administered drug available by prescription in the U.S. and throughout much of the world for treating alcohol dependence. Its safety and efficacy have been demonstrated in numerous clinical trials worldwide. Here we provide an overview of acamprosate in the context of the neurobiological underpinnings of alcohol dependence. We propose that unlike previously available pharmacotherapies, acamprosate represents a prototypical neuromodulatory approach in the treatment of alcohol dependence. A neuromodulatory approach seeks to restore the disrupted changes in neurobiology resulting from chronic alcohol intake. We believe that a neuromodulatory approach will provide a heuristic framework for developing more effective pharmacotherapies for alcohol dependence.Keywords
This publication has 99 references indexed in Scilit:
- Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivationJournal of Psychiatric Research, 2006
- Effect of acamprosate on neonatal excitotoxic cortical lesions in in utero alcohol-exposed hamstersNeuroscience Letters, 2005
- The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol‐Dependent Individuals: Results of a Meta‐AnalysisAlcohol, Clinical and Experimental Research, 2004
- RETRACTED ARTICLE: Acamprosate and its efficacy in treating alcohol dependent adolescentsEuropean Child & Adolescent Psychiatry, 2003
- The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in GermanyPharmacoEconomics, 1998
- Clinical Pharmacokinetics of AcamprosateClinical Pharmacokinetics, 1998
- AcamprosateDrugs, 1997
- Increased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological studyBrain Research, 1995
- Ethanol potentiates and blocks NMDA‐activated single‐channel currents in rat hippocampal pyramidal cellsFEBS Letters, 1989
- Low doses of ethanol activate dopaminergic neurons in the ventral tegmental areaBrain Research, 1985